The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement.

4 Wall Street analysts have issued ratings and price targets for Omeros in the last 12 months. Omeros Stock Forecast is based on your current time horizon.
Find the latest Earnings Report Date for Omeros Corporation Common Stock (OMER) at Nasdaq.com. View, Omeros Stock Forecast - Daily Balance Of Power, Historical Fundamental Analysis of Omeros, Sponsored content. Omeros Corp's earnings in 2020 is -$108,013,000. Omeros Corp's earnings in 2020 is -$108,013,000.On average, 1 Wall Street analysts forecast OMER's earnings for 2020 to be $-99,209,414, with the lowest OMER earnings forecast at $-99,209,414, and the highest OMER earnings forecast at $-99,209,414. Omeros Corp is a United States-based biopharmaceutical company. Omeros Corporation Stock Price Forecast, "OMER" Predictons for2020 Terms of Service | Privacy Policy. A rank of 37 means that 63% of stocks appear more favorable to our system. By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk

OMER 11.90 0.29 (2.50%).

It considers technical and fundamental factors and is a good starting point for evaluating a stock. NASDAQ Updated Sep 14, 2020 3:31 PM

Omeros Corp (OMER:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. On average, 2 Wall Street analysts forecast OMER's earnings for 2020 to be $-96,483,881, with the lowest OMER earnings forecast at

What is OMER's forecast return on equity (ROE) for 2020-2023? Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. Is Omeros Corp Stock a good buy in 2020, according to Wall Street analysts? Omeros Corporation (OMER) estimates and forecasts. Copyright © 2018. (NASDAQ: OMER) Omeros Corp's forecast annual revenue growth rate of -15.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.30%. Investors can use this forecasting interface to forecast Omeros historical stock prices and determine the direction of Omeros's future trends based on various well-known forecasting models. Omeros Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart.

On average, Wall Street analysts predict that Omeros Corp's share price could reach $24.50 by Sep 1, 2021. What is your perspective on investing in Omeros? Omeros Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. What this means: InvestorsObserver gives Omeros Corp (OMER) an overall rank of 37, which is below average. Do Analysts Expect Omeros Corporation (OMER) Stock to Rise?

On average, 2 Wall Street analysts forecast OMER's revenue for 2021 to be $4,472,872,781, with the lowest OMER revenue forecast at $494,956,856, and the highest OMER revenue forecast at $8,450,788,705. What is OMER's revenue growth forecast for 2020-2022?

Portfolio results are unaudited and based on varying investment expiration dates. Omeros Corp's revenue in 2020 is $100,339,000.On average, 2 Wall Street analysts forecast OMER's revenue for 2020 to be $4,158,891,339, with the lowest OMER revenue forecast at $3,783,040,290, and the highest OMER revenue forecast at $4,534,742,388. In 2022, OMER is forecast to generate $-159,171,148 in earnings, with the lowest earnings forecast at $-159,171,148 and the highest earnings forecast at $-159,171,148. The average Omeros Corp stock price prediction forecasts a potential downside of 49.76% from the current OMER share price of $12.31.

Upgrade to remove this ad, On September 24 2020 Omeros was traded for, 20 Period Moving Average (Increase Horizon).

Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Their average twelve-month price target is $21.33, predicting that the stock has a possible upside of 83.75%.